Loading...
The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions or methods using IL-4, a fragment or variant thereof, fused to a moiety, to increase the efficacy of an anti-cancer immunotherapy or an autoimmune therapy.
Type
patent
EPO Family ID
81850991
Inventors
Note
Alternative title(s) : (de) Hochwirksame adoptive t-zelltherapie ; (fr) Thérapie de lymphocytes t adoptive hautement efficace
TTO classification
TTO:6.2335
EPFL units
Patent number | Country code | Kind code | Date issued |
WO2023232810 | WO | A1 | 2023-12-07 |
EP4285913 | EP | A1 | 2023-12-06 |
Available on Infoscience
January 18, 2024
Use this identifier to reference this record